Allergic contact dermatitis from transdermal buprenorphine

Hulst, Kim Vander; Amer, Elisabeth Parera; Jacobs, C; Dewulf, Virginie; Baeck, Marie; Vallverdú, R. M. Pujol; Giménez-Arnau, A.M.; Tennstedt, Dominique; Goossens, An

doi:10.1111/j.1600-0536.2008.01472.x

Cited by 36 publications

(19 citation statements)

References 11 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…None of the patient in our study suffered allergic reaction or skin irritation to the drug patch; however these problems were noted in other studies [10,11,12].…”

Section: Discussionmentioning

confidence: 51%

Comparison between Transdermal Buprenorphine and Transdermal Fentanyl for Postoperative Pain Relief after Major Abdominal Surgeries

Arshad

Prakash²,

Kumar³

2015

JCDR

View full text Add to dashboard Cite

“…None of the patient in our study suffered allergic reaction or skin irritation to the drug patch; however these problems were noted in other studies [10,11,12].…”

Section: Discussionmentioning

confidence: 51%

Comparison between Transdermal Buprenorphine and Transdermal Fentanyl for Postoperative Pain Relief after Major Abdominal Surgeries

Arshad

Prakash²,

Kumar³

2015

JCDR

View full text Add to dashboard Cite

“…A few cases of contact dermatitis from buprenorphine have been described [3,4,6,7]. TDB has been described to cause allergic contact dermatitis mostly at the application site, but 2 cases of generalized eczema have been reported [4].…”

Section: Discussionmentioning

confidence: 99%

“…TDB has been described to cause allergic contact dermatitis mostly at the application site, but 2 cases of generalized eczema have been reported [4]. …”

Section: Discussionmentioning

confidence: 99%

“…Allergic contact dermatitis, which is diagnosed with patch testing, is relatively rare [1]. Oral opioid tolerance in patients with allergic contact dermatitis to TDB remains controversial [3,4]. After informed consent, we describe 3 patients with allergic contact dermatitis to buprenorphine who have subsequently used oral opioid derivatives without adverse reactions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Allergic Contact Dermatitis from Buprenorphine and Oral Tolerance to Other Opioid Derivatives in Three Patients

et al. 2013

View full text Add to dashboard Cite

Transdermal buprenorphine (TDB) is a widely used analgesic for moderate pain. TDB is generally well tolerated, but both irritant and allergic contact dermatitis occur at patch application sites. Oral opioid tolerance in patients with allergic contact dermatitis to TDB remains controversial. Here, we describe 3 patients with allergic contact dermatitis to TDB who subsequently used oral opioid derivatives without adverse reactions. Thus, oral intolerance to opioid derivatives is not a rule in patients with allergic contact dermatitis to TDB, but the possibility should be taken into consideration.

show abstract

“…Less common reactions include bronchospasm, angioedema, and anaphylactic shock (2). Such systemic reactions to buprenorphine, however, are rare (4, 5). We now report on a 21-year-old woman with a six-year history of opioid dependence, who had hypersensitivity reactions to many opioid medications, including buprenorphine, heroin, oxycodone, hydrocodone, and methadone, and who was successfully desensitized to buprenorphine.…”

Section: To the Editormentioning

confidence: 99%

Sublingual desensitization for buprenorphine hypersensitivity

Stutius

Pessach

Lee

et al. 2010

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Buprenorphine (Subutex), a semi-synthetic opiate alkaloid derivative with partial μ-opioid receptor agonist and κ-opioid receptor antagonist activity, is used for treatment of opioid dependence or as a long-acting analgesic (1). It is available in several forms including sublingual tablets and has a mean plasma elimination half-life of 37 hours (2). Like other opioids, it can cause hypersensitivity reactions by directly activating mast cells or basophils in an IgE-independent manner (3). Reactions to buprenorphine have been reported in clinical trials and post-marketing experience: the most common reactions include rashes, hives, and pruritus. Less common reactions include bronchospasm, angioedema, and anaphylactic shock (2). Such systemic reactions to buprenorphine, however, are rare (4,5). We now report on a 21-year-old woman with a six-year history of opioid dependence, who had hypersensitivity reactions to many opioid medications, including buprenorphine, heroin, oxycodone, hydrocodone, and methadone, and who was successfully desensitized to buprenorphine.In our patient, heroin caused severe hives, vomiting, coughing, and sensation of throat closing; oxycodone resulted in hives and vomiting; hydrocodone and methadone resulted in severe nausea and vomiting. After multiple unsuccessful attempts to quit using drugs on her own, she entered a substance abuse treatment program and achieved remission for eight months, treated with sublingual buprenorphine twice daily along with cetirizine daily to minimize adverse reactions. She initially tolerated buprenorphine with cetirizine without reactions, but six months into her treatment, after missing a dose of cetirizine, she developed hives, dizziness, and a sensation of throat closing. Although these symptoms improved with cetirizine, further buprenorphine doses were accompanied by skin tingling, flushing, hives, and sometimes also with facial edema, nausea, or respiratory symptoms (sensation of throat closing associated with coughing and difficulty breathing). Over the next two months, respiratory symptoms became more frequent and severe. Symptoms occurred several times per week, typically lasting 10 NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript minutes, and improving with cetirizine. Because of these reactions, buprenorphine was discontinued and these symptoms abated. However, she then relapsed into heroin use, which caused severe reactions with hives, vomiting, diarrhea, and a sensation of throat closing, despite remaining on daily cetirizine. She was referred for further evaluation of buprenorphine allergy.Physical examination was notable for mild dermatographia. Laboratory evaluation was notable for baseline total tryptase that was initially mildly elevated at 18 ng/mL (reference range, 1-15 ng/mL); repeat 13 ng/mL. CBC showed 5% eosinophils, but was otherwise normal, as were LFTs and TSH. Because she required a minimum of several months of sublingual buprenorphine to treat her substance dependence, desensitization to buprenorphine was...

show abstract

Allergic contact dermatitis from transdermal buprenorphine

Abstract: We report five cases of delayed hypersensitivity reactions to a TDS containing buprenorphine. Such adverse reactions might be under-reported. A fentanyl-containing TDS is a good alternative in these cases.

Cited by 36 publications

References 11 publications

Comparison between Transdermal Buprenorphine and Transdermal Fentanyl for Postoperative Pain Relief after Major Abdominal Surgeries

Comparison between Transdermal Buprenorphine and Transdermal Fentanyl for Postoperative Pain Relief after Major Abdominal Surgeries

Allergic Contact Dermatitis from Buprenorphine and Oral Tolerance to Other Opioid Derivatives in Three Patients

Sublingual desensitization for buprenorphine hypersensitivity

Contact Info

Product

Resources

About